PROSPERO International prospective register of systematic reviews
Epidemiology of neuroendocrine liver tumours (NET) and NET liver metastases
Josephine Wachtl, Elena Scherrer, Irvin M Modlin, Benjamin Lawrence, Wouter de Herder, Tetsuhide Ito, Bjørn Gustafsson, Milo Puhan, Andrea Frilling, Mickael Lesurtel, Dimitri Raptis, Stefan Breitenstein
Citation
Josephine Wachtl, Elena Scherrer, Irvin M Modlin, Benjamin Lawrence, Wouter de Herder, Tetsuhide Ito, Bjørn Gustafsson, Milo Puhan, Andrea Frilling, Mickael Lesurtel, Dimitri Raptis, Stefan Breitenstein. Epidemiology of neuroendocrine liver tumours (NET) and NET liver metastases.
PROSPERO
2012:CRD42012002643
Available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012002643
Review question(s)
What is the incidence of NET?
What is the prevalence of NET?
What is the incidence of NET liver metastases at presentation?
What is the prevalence of NET liver metastases?
What are the incidence rates of NET according to the site of the primary tumour?
What are the incidence rates of liver metastases according to the site of the primary tumour?
Searches
We will search the following electronic bibliographic databases: MEDLINE, EMBASE and The Cochrane Library (Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects and Cochrane Central Register of Controlled Trials (CENTRAL)). There will be no language restrictions.
Types of study to be included
Population-based studies/epidemiological studies.
Condition or domain being studied
Neuroendocrine tumors and neuroendocrine liver metastases
Participants/ population
Inclusion criteria: country or city populations
Intervention(s), exposure(s)
Not applicable
Comparator(s)/ control
The different sites of the primary tumours.
Context
Studies will be included that are based on a representative size of population (e.g. of a whole region, country, continent).
Outcome(s)
Primary outcomes
1. Incidence of NET.
2. Incidence of NET liver metastases.
Secondary outcomes
1. Incidence of NET according to the site of the primary tumour.
2. Prevalence of NET according to the site of the primary tumour.
3. Incidence of liver metastases according to the site of the primary tumour.
4. Prevalence of liver metastases according to the site of the primary tumour.
Data extraction, (selection and coding)
Titles and/or abstracts of studies retrieved using the search strategy will be screened independently by two review team members to identify studies that potentially meet the inclusion criteria outlined above. The full text of these potentially eligible studies will be retrieved and independently assessed for eligibility. Any disagreement over the eligibility of particular studies will be resolved through discussion. A pre-defined protocol will be used to extract data from the included studies for assessment of study quality and evidence synthesis.
Risk of bias (quality) assessment
To grade the quality (level) of evidence and the strength of recommendations we will use the GRADE (The Grading of Recommendations Assessment, Development and Evaluation, http://www.gradeworkinggroup.org/intro.htm) system to assess the final recommendations.
Strategy for data synthesis
We will provide a narrative synthesis of the findings from the included studies. A quantitative synthesis (meta-analysis) will be used if the included studies are sufficiently homogenous.
Analysis of subgroups or subsets
None planned
Dissemination plans
The results of this systematic review will be first presented at the International Consensus Conference on NET Liver Metastases (http://www.netlivermets.com/) and the submitted for consideration for publication at a peer reviewed journal.
Contact details for further information
Dimitri Raptis
University Hospital Zurich
Department of Surgery
Swiss HPB Center
Raemistrasse 100
CH-8091, Zurich
Switzerland
dimitri.raptis@usz.ch
Organisational affiliation of the review
University Hospital Zurich, Department of Surgery, Swiss HPB Center, Zurich, Switzerland
http://www.en.usz.ch/
Review team
Miss Josephine Wachtl, University of Zurich, Switzerland Miss Elena Scherrer, University of Zurich, Switzerland Professor Irvin M Modlin, Yale University, USA Dr Benjamin Lawrence, University of Auckland, New Zealand Dr Wouter de Herder, Erasmus MC, The Netherlands Dr Tetsuhide Ito, Kyushu University, Japan Dr Bjørn Gustafsson, Univesity Tronttheim, Norway Professor Milo Puhan, Johns Hopkins Bloomberg School of Public Health, USA Professor Andrea Frilling, Imperial College London, UK Professor Mickael Lesurtel, University Hospital Zurich, Switzerland Dr Dimitri Raptis, University Hospital Zurich, Switzerland Dr Stefan Breitenstein, University Hospital Zurich, Switzerland
Anticipated or actual start date
21 March 2012
Anticipated completion date
10 December 2012
Funding sources/sponsors
Department of Surgery, University Hospital Zurich, Switzerland
Formal screening of search results against eligibility criteria
Data extraction
Risk of bias (quality) assessment
Data analysis
Prospective meta-analysis
PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites.
